Mark Fleming, MD
Hematology & Oncology · Hampton, VANPI 1457383663
Payments from drug & device makers
Across 867 payments — averaging $11,505 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$5.5M
- E.r. Squibb & Sons, L.L.C.$1.7M
- Janssen Research & Development, LLC$751K
- AstraZeneca$474K
- Astrazeneca UK Limited$411K
- Exelixis Inc.$282K
- plus $866K from 20 others
Across 10 payments — averaging $946.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis Pharma AG$5K
- Pfizer$4K
- Novartis$763
What the payments were for
- Consulting fees$53,62976%
- Speaking & faculty fees$12,75018%
- Travel & lodging$3,1694%
- Food & beverage$1,1162%
- Education$2340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 26 | $5,477,809 |
| E.r. Squibb & Sons, L.L.C. | 83 | $1,711,625 |
| Janssen Research & Development, LLC | 304 | $751,222 |
| AstraZeneca | 22 | $473,805 |
| Astrazeneca UK Limited | 4 | $411,271 |
| Exelixis Inc. | 27 | $282,362 |
| Blue Earth Diagnostics | 25 | $279,239 |
| Incyte Corporation | 122 | $168,250 |
| Merck | 88 | $105,284 |
| Amgen | 10 | $99,415 |
| Genentech, Inc. | 34 | $50,616 |
| Pfizer | 28 | $36,549 |
| Seagen Inc. | 27 | $31,814 |
| Johnson & Johnson(2 entities) | 23 | $22,772 |
| Gilead | 19 | $22,512 |
| Daiichi Sankyo Inc. | 8 | $21,022 |
| Bayer | 5 | $17,991 |
| Progenics Pharmaceuticals, Inc. | 1 | $3,300 |
| Mirati Therapeutics, Inc. | 2 | $2,081 |
| Dendreon Pharmaceuticals LLC | 1 | $1,750 |
| Sanofi | 3 | $1,648 |
| Immunomedics, Inc. | 1 | $1,250 |
| Advanced Accelerator Applications | 1 | $600 |
| Array Biopharma Inc | 1 | $150 |
| Mallinckrodt Enterprises LLC | 1 | $119 |
| Foundation Medicine, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,974,467 in reported general payments places this provider in the 95th percentile of 293 hematology & oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 60 | $1,359,320 |
| ErleadaApalutamide | 84 | $1,020,525 |
| XtandiEnzalutamide | 55 | $655,602 |
| LenvimaLenvatinib Mesylate | 24 | $552,663 |
| WeliregBelzutifan | 24 | $508,224 |
| Abiraterone Acetate | 138 | $311,557 |
| InlytaAxitinib | 30 | $257,377 |
| NubeqaDarolutamide | 16 | $197,274 |
| CalquenceAcalabrutinib Maleate | 12 | $172,873 |
| Pazopanib Hcl | 13 | $70,860 |
| OrgovyxRelugolix | 24 | $65,279 |
| EliquisApixaban | 54 | $34,217 |
| XareltoRivaroxaban | 32 | $31,590 |
| Prednisone | 197 | $958 |
| Megestrol Acetate | 14 | $939 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $282,362 | $1,359,32060 claims |
| Johnson & JohnsonErleada, Xarelto | $22,772 | $1,052,115116 claims |
| MerckWelireg | $105,284 | $508,22424 claims |
| PfizerInlyta, Eliquis | $36,549 | $291,59484 claims |
| BayerNubeqa | $17,991 | $197,27416 claims |
| AstraZenecaCalquence | $473,805 | $172,87312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 293 hematology & oncology providers in Virginia.
Other hematology & oncology in Hampton
- Ruby KochharHampton$236K
- Craig PortellCharlottesville$12.9M
- Amanda Gillespie-TwardyRoanoke$12.2M
- Sekwon JangFairfax$11.8M
- Mark KochenderferRoanoke$8.6M
- Mitul GandhiManassas$6.9M
- Michael DansoNorfolk$6.9M
- Jerome GoldschmidtChristiansburg$6.5M
- William IrvinMidlothian$4.3M
- Lakshminarayanan NandagopalFredericksburg$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.